Lyophilized hydroxyureamethyl acylfulvene
The lyophilized formulation of illudins, specifically using cyclodextrin and mannitol, overcomes the stability and solubility issues of illudin family compounds, ensuring effective and stable cancer therapeutics.
WO2025064461A1 Publication Date: 2025-03-27LANTERN PHARMA INC
5 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2024/047149
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-18
- Filing Date
- 2024-09-18
- Publication Date
- 2025-03-27
AI Technical Summary
Technical Problem
Illudin family compounds, including hydroxyureamethyl acylfulvene, are unstable and difficult to lyophilize due to limited solubility in water and sensitivity to heat, light, and pH changes, which complicates their use as cancer therapeutics.
Method used
A lyophilized formulation comprising illudins or their analogs, such as hydroxyureamethyl acylfulvene, combined with cyclodextrin, mannitol, and an organic solvent, which enhances solubility, stability, and reconstitution ease.
Benefits of technology
The formulation achieves stable and effective lyophilization of illudins, maintaining therapeutic efficacy and stability during storage and reconstitution, thereby addressing the challenges of instability and solubility.
✦ Generated by Eureka AI based on patent content.
Abstract
Lyophilized preparations include illudins, including hydroxyureamethyl acylfulvene, and pharmaceutically acceptable salts thereof, in combination with cyclodextrins. These formulations are designed to enhance the solubility, stability, and therapeutic efficacy of illudins, which are known for their potent anticancer properties. Methods for producing these lyophilized preparations, including freeze-drying processes, are provided.
Need to check novelty before this filing date? Find Prior Art